; (4) a summary of serious adverse event reports submitted under section 762, and the associated product category and serious adverse health consequence for each such report; and (5) enforcement actions, if any, the Commissioner has taken as a result of serious adverse event reports or facility inspections, including warning letters, untitled letters, suspension of registration, or any other type of action. . 10. GAO report Not later than 2 years after the date of enactment of this Act, the Comptroller General of the United States shall analyze, and submit a report to Congress on— (1) the types of ingredients or non-functional constituents that the Food and Drug Administration has identified for purposes of a safety review under section 606 of the Federal Food, Drug, and Cosmetic Act (as added by section 7) and the factors or methods, if any, that such agency considers in determining the need for a safety review; (2) the level of coordination between the Food and Drug Administration and the States in identifying ingredients that may present a public health concern for review, and the process by which the Food and Drug Administration considers public input as part of identifying ingredients that may present a public health concern; (3) how the Food and Drug Administration accounts for reports of serious adverse events under section 762 of the Federal Food, Drug, and Cosmetic Act (as added by section 2) to inform cosmetic related inspections; (4) the frequency and type of inspections conducted by the Food and Drug Administration, including inspections in response to reports of serious adverse events, and an analysis of the outcome and related facility compliance; (5) the time between identifying ingredients to be reviewed for safety under section 606(a) of the Federal Food, Drug, and Cosmetic Act and issuance of final administrative orders under section 606(b)(2) of such Act